Cargando…
Tafolecimab, A Novel Member of PCSK9 Monoclonal Antibodies, Is Worth Expecting in a Chinese Population
[Figure: see text]
| Autor principal: | |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Elsevier
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10442878/ https://www.ncbi.nlm.nih.gov/pubmed/37614538 http://dx.doi.org/10.1016/j.jacasi.2023.06.002 |
| _version_ | 1785093696617709568 |
|---|---|
| author | Li, Jian-Jun |
| author_facet | Li, Jian-Jun |
| author_sort | Li, Jian-Jun |
| collection | PubMed |
| description | [Figure: see text] |
| format | Online Article Text |
| id | pubmed-10442878 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2023 |
| publisher | Elsevier |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-104428782023-08-23 Tafolecimab, A Novel Member of PCSK9 Monoclonal Antibodies, Is Worth Expecting in a Chinese Population Li, Jian-Jun JACC Asia Original Research [Figure: see text] Elsevier 2023-07-11 /pmc/articles/PMC10442878/ /pubmed/37614538 http://dx.doi.org/10.1016/j.jacasi.2023.06.002 Text en © 2023 The Author https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
| spellingShingle | Original Research Li, Jian-Jun Tafolecimab, A Novel Member of PCSK9 Monoclonal Antibodies, Is Worth Expecting in a Chinese Population |
| title | Tafolecimab, A Novel Member of PCSK9 Monoclonal Antibodies, Is Worth Expecting in a Chinese Population |
| title_full | Tafolecimab, A Novel Member of PCSK9 Monoclonal Antibodies, Is Worth Expecting in a Chinese Population |
| title_fullStr | Tafolecimab, A Novel Member of PCSK9 Monoclonal Antibodies, Is Worth Expecting in a Chinese Population |
| title_full_unstemmed | Tafolecimab, A Novel Member of PCSK9 Monoclonal Antibodies, Is Worth Expecting in a Chinese Population |
| title_short | Tafolecimab, A Novel Member of PCSK9 Monoclonal Antibodies, Is Worth Expecting in a Chinese Population |
| title_sort | tafolecimab, a novel member of pcsk9 monoclonal antibodies, is worth expecting in a chinese population |
| topic | Original Research |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10442878/ https://www.ncbi.nlm.nih.gov/pubmed/37614538 http://dx.doi.org/10.1016/j.jacasi.2023.06.002 |
| work_keys_str_mv | AT lijianjun tafolecimabanovelmemberofpcsk9monoclonalantibodiesisworthexpectinginachinesepopulation |